Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07224035 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1

StatusCompleted
PhasePhase 4
Started2022-10-15
View on ClinicalTrials.gov ↗

Amendment history

2026-10-01
Trial completed
Final enrollment: 430 participants (planned 500)
Primary completion confirmed: February 2026 (last estimated November 2027)
2026-02-12
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2025-11-03
Study Status, Study Description v1
Re-verified, no change to tracked fields
2025-10-30
Original filing
H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for the infection. By treating those who are positive for H. pylori, there is an opportunity to prevent gastritis, peptic ulcer disease, and even gastric cancer.
Trial Details
NCT Number NCT07224035
Lead Sponsor University of Miami
Collaborators: Phathom Pharmaceuticals, NRG Oncology
Conditions H Pylori Infection, H Pylori Gastritis, Gastric Cancer
Enrollment 430 participants
Start Date 2022-10-15
Primary Completion 2026-02-09 (estimated)
Study Completion 2026-02-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-30